Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in obesity. See why AMGN stock is a buy.

Amgen’s Imdelltra, a delta-like ligand 3 targeting Bispecific T-cell Engager (BiTE) therapy, was approved by the FDA in 2024 for pre-treated extensive-stage small cell lung cancer (ES-SCLC ...

Key Takeaways Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8 ...

IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

IMDELLTRA® (tarlatamab-dlle) Important Safety Information (USPI) WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.